Are We Measuring What Matters Most in ITP? – ITP Australia and New Zealand
ITP Australia and New Zealand shared a post on LinkedIn:
“Are we measuring what matters most in ITP?
Historically, the management of Immune Thrombocytopenia (ITP) has focused heavily on readily quantifiable outcomes such as platelet counts and bleeding events.
Yet for many patients, these measures tell only part of the story.
In a recent interview discussing quality-of-life data from the phase 2 mezagitamab study presented at ISTH 2026, International ITP Medical Advisor Dr David Kuter highlights the importance of evaluating outcomes that directly affect patients’ daily lives, including fatigue, physical functioning, psychological wellbeing, and overall quality of life.
One of the key messages from the discussion is that ‘ITP is not just the platelet count.’
The study demonstrated meaningful improvements across multiple patient-reported outcome measures, reinforcing the growing recognition that successful ITP management involves more than achieving a numerical platelet target.
As the field continues to evolve, incorporating patient-reported outcomes into research, clinical practice, and treatment decision-making will be critical to ensuring care reflects what matters most to patients.
How can we better integrate quality-of-life measures into routine ITP care and treatment evaluation?”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease